Results 21 to 30 of about 25,220 (171)
Emerging Microbes and Infections, 2017 Humoral responses are essential for the protective efficacy of most Ebola virus (EBOV) candidate vaccines; however, the in vivo development of protective anti-EBOV B-cell responses is poorly defined.
Christopher L Cooper +6 more
doaj +1 more source
Human Vaccines & Immunotherapeutics, 2017 Immunoinformatics tools were used to predict human leukocyte antigen (HLA) class II-restricted T cell epitopes within the envelope glycoproteins and nucleocapsid proteins of Ebola virus (EBOV) and Sudan virus (SUDV) and the structural proteins of ...
Callie E. Bounds +8 more
doaj +1 more source
mBio, 2018 Ebola virus (EBOV) genome and mRNAs contain long, structured regions that could hijack host RNA-binding proteins to facilitate infection. We performed RNA affinity chromatography coupled with mass spectrometry to identify host proteins that bind to EBOV ...
Jingru Fang +7 more
doaj +1 more source
Scientific Reports, 2017 Ebola virus (EBOV) poses a significant threat to human health as highlighted by the recent epidemic in West Africa. Data from animal studies and a ring vaccination clinical trial conducted in Guinea during the recent epidemic demonstrated that a ...
Andrea R. Menicucci +4 more
doaj +1 more source
Portrait of a Killer: Genome of the 2014 EBOV Outbreak Strain [PDF]
Cell Host & Microbe, 2014 A recent study by Gire et al. (2014) identifies differences that make the 2014 West Africa Ebola virus unique and details how the virus spread from Guinea to Sierra Leone. This work highlights the power of new genomic technologies to facilitate rapid public health and scientific responses to the crisis.
openaire +2 more sources
Serine-Arginine Protein Kinase 1 Regulates Ebola Virus Transcription
mBio, 2020 Ebola virus (EBOV) causes a severe and often fatal disease for which no approved vaccines or antivirals are currently available. EBOV VP30 has been described as a viral phosphoprotein, and nonphosphorylated VP30 is essential and sufficient to support ...
Yuki Takamatsu +8 more
doaj +1 more source
PLoS ONE, 2021 Ebola virus (EBOV), a member of the mononegaviral family Filoviridae, causes severe disease associated with high lethality in humans. Despite enormous progress in development of EBOV medical countermeasures, no anti-EBOV treatment has been approved.
Yingyun Cai +5 more
doaj +1 more source
Strength through Organization: Classifying Antibody Activity against EBOV [PDF]
Cell Host & Microbe, 2018 In this issue of Cell Host & Microbe and in a related Cell paper, works by Gunn et al. (2018) and Saphire et al. (2018) describe a large number of monoclonal antibodies against Ebola virus (EBOV) and correlate their activity with in vivo protection.
openaire +2 more sources
PLOS ONE, 2016 Polyclonal xenogenic IgGs, although having been used in the prevention and cure of severe infectious diseases, are highly immunogenic, which may restrict their usage in new applications such as Ebola hemorrhagic fever. IgG glycans display powerful xenogeneic antigens in humans, for example α1-3 Galactose and the glycolyl form of neuraminic acid Neu5Gc,
Reynard, Olivier +20 more
openaire +6 more sources
The transcriptomic profiling of SARS-CoV-2 compared to SARS, MERS, EBOV, and H1N1
PLOS ONE, 2020 The SARS-CoV-2 (COVID-19) pandemic is a global crisis that threatens our way of life. As of November 18, 2020, SARS-CoV-2 has claimed more than 1,342,709 lives, with a global mortality rate of ~2.4% and a recovery rate of ~69.6%.
Alsamman M. Alsamman, Hatem Zayed
openaire +6 more sources